Cargando…

Regulation of CaMKII signaling in cardiovascular disease

Heart failure (HF) is a major cause of death in the developed countries (Murray and Lopez, 1996; Koitabashi and Kass, 2012). Adverse cardiac remodeling that precedes heart muscle dysfunction is characterized by a myriad of molecular changes affecting the cardiomyocyte. Among these, alterations in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollova, Mariya Y., Katus, Hugo A., Backs, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548452/
https://www.ncbi.nlm.nih.gov/pubmed/26379551
http://dx.doi.org/10.3389/fphar.2015.00178
_version_ 1782387196527902720
author Mollova, Mariya Y.
Katus, Hugo A.
Backs, Johannes
author_facet Mollova, Mariya Y.
Katus, Hugo A.
Backs, Johannes
author_sort Mollova, Mariya Y.
collection PubMed
description Heart failure (HF) is a major cause of death in the developed countries (Murray and Lopez, 1996; Koitabashi and Kass, 2012). Adverse cardiac remodeling that precedes heart muscle dysfunction is characterized by a myriad of molecular changes affecting the cardiomyocyte. Among these, alterations in protein kinase pathways play often an important mediator role since they link upstream pathologic stress signaling with downstream regulatory programs and thus affect both the structural and functional integrity of the heart muscle. In the context of cardiac disease, a profound understanding for the overriding mechanisms that regulate protein kinase activity (protein-protein interactions, post-translational modifications, or targeting via anchoring proteins) is crucial for the development of specific and effective pharmacological treatment strategies targeting the failing myocardium. In this review, we focus on several mechanisms of upstream regulation of Ca(2+)-calmodulin-dependent protein kinase II that play a relevant pathophysiological role in the development and progression of cardiovascular disease; precise targeting of these mechanisms might therefore represent novel and promising tools for prevention and treatment of HF.
format Online
Article
Text
id pubmed-4548452
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45484522015-09-14 Regulation of CaMKII signaling in cardiovascular disease Mollova, Mariya Y. Katus, Hugo A. Backs, Johannes Front Pharmacol Pharmacology Heart failure (HF) is a major cause of death in the developed countries (Murray and Lopez, 1996; Koitabashi and Kass, 2012). Adverse cardiac remodeling that precedes heart muscle dysfunction is characterized by a myriad of molecular changes affecting the cardiomyocyte. Among these, alterations in protein kinase pathways play often an important mediator role since they link upstream pathologic stress signaling with downstream regulatory programs and thus affect both the structural and functional integrity of the heart muscle. In the context of cardiac disease, a profound understanding for the overriding mechanisms that regulate protein kinase activity (protein-protein interactions, post-translational modifications, or targeting via anchoring proteins) is crucial for the development of specific and effective pharmacological treatment strategies targeting the failing myocardium. In this review, we focus on several mechanisms of upstream regulation of Ca(2+)-calmodulin-dependent protein kinase II that play a relevant pathophysiological role in the development and progression of cardiovascular disease; precise targeting of these mechanisms might therefore represent novel and promising tools for prevention and treatment of HF. Frontiers Media S.A. 2015-08-25 /pmc/articles/PMC4548452/ /pubmed/26379551 http://dx.doi.org/10.3389/fphar.2015.00178 Text en Copyright © 2015 Mollova, Katus and Backs. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mollova, Mariya Y.
Katus, Hugo A.
Backs, Johannes
Regulation of CaMKII signaling in cardiovascular disease
title Regulation of CaMKII signaling in cardiovascular disease
title_full Regulation of CaMKII signaling in cardiovascular disease
title_fullStr Regulation of CaMKII signaling in cardiovascular disease
title_full_unstemmed Regulation of CaMKII signaling in cardiovascular disease
title_short Regulation of CaMKII signaling in cardiovascular disease
title_sort regulation of camkii signaling in cardiovascular disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548452/
https://www.ncbi.nlm.nih.gov/pubmed/26379551
http://dx.doi.org/10.3389/fphar.2015.00178
work_keys_str_mv AT mollovamariyay regulationofcamkiisignalingincardiovasculardisease
AT katushugoa regulationofcamkiisignalingincardiovasculardisease
AT backsjohannes regulationofcamkiisignalingincardiovasculardisease